GlassScriptPhysician profile
James E Allen
NPI 1922489244
$8,520.89
in general payments reported to CMS, 2019-2025
30 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.36 · 2020: $1,785 · 2021: $1,942 · 2022: $574 · 2023: $909 · 2024: $1,396 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160 · Education: $49.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,159.76 |
| Education | $49.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $3,333.34 | 2020-2021 | |
| Abbvie INC. | $1,785.73 | 2021-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,148.16 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.65 | 2020-2025 | Xifaxan, Trulance, Uceris |
| Pfizer INC. | $300.00 | 2022-2025 | |
| Ardelyx, INC. | $169.13 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $165.49 | 2025 | Omvoh |
| Medtronic, INC. | $164.22 | 2021-2025 | Pillcam |
| Celltrion USA INC. | $129.49 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Regeneron Healthcare Solutions, INC. | $123.50 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $112.70 | 2024-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $99.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $88.95 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $87.90 | 2025 | |
| Ferring Pharmaceuticals INC. | $78.74 | 2023 | Rebyota |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $69.70 | 2025 | Esophyx |
| Celgene Corporation | $63.97 | 2023-2024 | Zeposia |
| Mauna Kea Technologies, INC. | $45.61 | 2021 | |
| Genzyme Corporation | $45.27 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $36.69 | 2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $30.10 | 2021-2022 | |
| Micro-Tech Endoscopy USA, INC. | $20.17 | 2024-2025 | Riteclip, Abc Balloons |
| Qol Medical, LLC | $18.30 | 2025 | Sucraid |
| Amgen INC. | $17.57 | 2022 | |
| Fresenius Kabi USA, LLC | $16.70 | 2023 | Idacio |
| Azurity Pharmaceuticals, INC. | $15.35 | 2025 | Suflave |
| Madrigal Pharmaceuticals | $13.88 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $13.16 | 2022 | |
| Redhill Biopharma INC. | $12.06 | 2022 | |
| Csl Behring | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.